| Line Item | 2025-01-31 | Y/Y |
|---|---|---|
| Revenue | $886.5M | +41.2% |
| Cost of Revenue | $265.7M | +83.3% |
| Gross Profit | $620.8M | +28.5% |
| R&D Expense | $531.6M | +157.4% |
| SG&A Expense | $355.7M | +254.4% |
| Operating Income | -$1.13B | -270.0% |
| Pre-tax Income | -$1.15B | -250.7% |
| Income Tax | $6.4M | -76.1% |
| Net Income | -$1.15B |
| Line Item | 2025-01-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $186.3M | +43.3% |
| Accounts Receivable | $177.6M | +33.0% |
| Inventory | $4.2M | -13.0% |
| Current Assets | $1.08B | +96.4% |
| Total Assets | $1.42B | +62.9% |
| Current Liabilities | $950.2M | +44.8% |
| Long-term Debt | $322.3M | +12.3% |
| Line Item | 2025-01-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $48.2M | +1167.5% |
| Capital Expenditures | $16.9M | +36.9% |
| Investing Cash Flow | -$383.4M | -309.6% |
| Financing Cash Flow | $398.0M | +314.8% |
| Free Cash Flow | $31.3M | +286.0% |
| -226.1% |
| EPS (Basic) | -$7.48 | -28.1% |
| EPS (Diluted) | -$7.48 | -28.1% |
| Total Liabilities |
| $1.98B |
| +25.3% |
| Stockholders' Equity | -$553.7M | +61.0% |